此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection

AMENDED: As of 10/19/90 only Children 0 to 3 months are being enrolled. Original design: To determine whether the experimental drug recombinant CD4 (rCD4), which is produced through genetic engineering technology, is safe and well-tolerated in children infected with or at risk for HIV infection.

rCD4 may be an effective treatment for HIV infection, based on its ability to block infection of human cells by HIV in laboratory tests. However, the activity of rCD4 still needs to be confirmed in clinical trials. It is hoped that these tests will show that rCD4 is both safe and effective in treating children who are infected with or who are at risk for infection with HIV.

研究概览

地位

完全的

干预/治疗

详细说明

rCD4 may be an effective treatment for HIV infection, based on its ability to block infection of human cells by HIV in laboratory tests. However, the activity of rCD4 still needs to be confirmed in clinical trials. It is hoped that these tests will show that rCD4 is both safe and effective in treating children who are infected with or who are at risk for infection with HIV.

Children have preliminary testing and evaluation to determine eligibility and health. The dosage schedule varies with the dose. During the course of the study, children are monitored for safety through physical exams and blood tests. They have blood withdrawn to study the response to rCD4 and measure the activity of rCD4 in the body. Children may receive immunization of DPT (diphtheria, pertussis, tetanus) or DT and a polio vaccine to measure their antibody response. If the rCD4 is beneficial, children may continue treatment. The study is conducted in four parts:

  • Part A: Children 13 to 18 years old.
  • Part B: Children 3 months to less than 13 years old.
  • Part C: Full-term infants over 3 months old.
  • Part D: Preterm infants less than 3 months old. Parts C and D are not started until parts A and B have been completed.

研究类型

介入性

注册

40

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • San Francisco、California、美国、94143
        • Northern California Pediatric AIDS Treatment Ctr / UCSF
      • Stanford、California、美国、943054149
        • Stanford Univ School of Medicine / Pediatrics
    • Illinois
      • Chicago、Illinois、美国、606143394
        • Chicago Children's Memorial Hosp
      • Chicago、Illinois、美国、60614
        • Children's Memorial Med Ctr
    • New Jersey
      • Newark、New Jersey、美国、071072198
        • Children's Hosp of New Jersey / UMDNJ - New Jersey Med Schl
    • North Carolina
      • Durham、North Carolina、美国、277103499
        • Duke Univ Med Ctr

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1天 至 18年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria

Concurrent Medication:

Allowed:

  • Prophylactic medication for patients with previous documented episodes of Pneumocystis carinii pneumonia (PCP).
  • Concomitant zidovudine (AZT) or intravenous gamma globulin (IVIG) during maintenance therapy phase of the study.

AMENDED: As of 10/19/90 only Children 0 to 3 months are being enrolled.

Original design: Patients must be infected with HIV or at risk for HIV infection. They must be one of the following:

  • Asymptomatic.
  • Mildly symptomatic but not eligible for and/or decline ACTG protocol 052.
  • Markedly symptomatic but not eligible for and/or decline ACTG protocol 051 or cannot tolerate zidovudine (AZT) therapy.

All patients must have:

  • A life expectancy of at least 3 months.
  • A legally-qualified guardian with the ability to sign a written informed consent form, which must be obtained prior to treatment. A willingness to abstain from all other experimental therapy for HIV infection during the entire study period.

Exclusion Criteria

Concurrent Medication:

Excluded:

  • Zidovudine (AZT).
  • Intravenous gamma globulin (IVIG).
  • Pentamidine.
  • Trimethoprim / sulfamethoxazole (TMP/SMX).
  • Corticosteroids.
  • Nonsteroidal anti-inflammatory agents (NSAIDS).
  • Other known immunomodulatory agents.
  • All other experimental therapies.

Patients will be excluded from the study for the following reasons:

  • Serious active opportunistic infection or malignancies prior to study entry.
  • Defined organ insufficiencies.

Prior Medication:

Excluded within 3 weeks of study entry:

  • Zidovudine (AZT).
  • Intravenous gamma globulin.
  • Cancer chemotherapy.
  • Immunomodulatory agents.
  • Other experimental therapy.

Patients may not have any of the following diseases or symptoms:

  • Serious active opportunistic infection or malignancies prior to study entry.
  • Cardiopathy.
  • Two or more episodes of prior Pneumocystis carinii pneumonia (PCP).
  • Hematologic insufficiency defined as granulocytes = or < 1000 cells/mm3; platelets = or < 100000 cells/mm3; hemoglobin = or < 8 g/dl.
  • Renal insufficiency defined as creatinine > 2 mg/dl; = or > 5 white blood cells or red blood cells/hpf or = or > 2+ proteinuria in urine.
  • Hepatic insufficiency defined as bilirubin = or > 3 x upper limit of normal; SGOT = or > 10 upper limit of normal.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 屏蔽:无(打开标签)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

调查人员

  • 学习椅:P Weintrub

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

  • Weintrub P, Yogev R, Conner E, Wilfert K, Mordenti J, Ammann AJ. Safety and pharmacokinetics of recombinant CD4 in children with HIV infection. Int Conf AIDS. 1990 Jun 20-23;6(2):95 (abstract no FB23)

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究注册日期

首次提交

1999年11月2日

首先提交符合 QC 标准的

2001年8月30日

首次发布 (估计)

2001年8月31日

研究记录更新

最后更新发布 (估计)

2005年6月24日

上次提交的符合 QC 标准的更新

2005年6月23日

最后验证

1996年10月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅